PERFECT (inhaled treprostinil)
Tyvaso® therapeutic platform
PERFECT (inhaled treprostinil)
PERFECT–Phase III, randomized, placebo-controlled, double-blind, adaptive study to evaluate the safety and efficacy of Tyvaso® (treprostinil) in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD).
Treprostinil’s mechanism of action suggests that treprostinil may be effective for treating pulmonary hypertension associated with lung disease, including pulmonary hypertension associated with chronic obstructive pulmonary disease (WHO Group 3 Pulmonary Hypertension). The use of inhaled treprostinil may be the preferred route of administration for treating PH in COPD patients as it provides a high dose of treprostinil to the damaged lungs.
Tyvaso® for PH WHO Group 3 is investigational and not FDA approved.
